The authors asked how common cannabis use and cannabis use disorder are in early-onset psychosis and what they correlate with clinically. That is a very different question from whether cannabis causes psychosis on its own or predicts one specific outcome in every patient.

The review pooled prevalence data and examined correlates such as sex, hospitalization, symptom pattern, and timing. It also used a narrative synthesis to describe how cannabis use appeared in relation to illness onset and course.

Across 40 studies and 3,473 participants, current cannabis use was common and lifetime cannabis use was even more common. Lifetime cannabis use disorder was also substantial, which is important because casual use and disorder are not the same clinical problem.

The review also found associations with hospitalization patterns and symptom profile. Those are not proof of causality, but they do indicate that cannabis exposure is intertwined with the clinical presentation rather than sitting at the edge of it.

Psychosis care often hinges on early identification of modifiable factors. If cannabis use is common and may precede symptom onset in some cases, then asking about it directly is part of good clinical work, not an optional extra.

The prevalence numbers also matter for families. A teenager or young adult with psychosis symptoms who uses cannabis is not unusual, and that overlap deserves structured assessment rather than vague reassurance or alarm.

This is an observational synthesis. It cannot separate cannabis effects from illness severity, family history, co-use, social stress, medication exposure, or reverse causality with enough precision to support deterministic claims.

The review is best read as a high-value screening and counseling paper. It says the overlap is real and clinically relevant, but it does not let us assign a simple cause-and-effect story to any one patient.

Early-onset psychosis already sits inside a complicated web of developmental change, family stress, school disruption, and often other substance use. That makes it easy to over-read any cannabis signal in isolation.

A systematic review like this is useful because it helps separate what is common from what is merely memorable. The common part here is the overlap between cannabis use and early-onset psychosis; the unresolved part is how much of the course is explained by cannabis itself versus the broader clinical context.

When I talk with families about psychosis risk, I try not to flatten the evidence into fear. This review does not prove that cannabis causes psychosis in a simple way, but it also does not support ignoring cannabis use when early symptoms appear.

The practical move is to ask better questions: What was the timing of cannabis use? How frequent is it? Is there cannabis use disorder? What else is happening clinically? That is how the evidence becomes useful at the bedside.

How to Read This Psychosis Review Carefully